Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
The planned merger of Jounce Therapeutics and UK-based Redx Pharma came under threat yesterday, when Jounce confirmed that it has received an unsolicited offer from Concentra Biosciences to acquire 100% of the company. 16 March 2023
Biotechnology
During the 2023 JP Morgan Healthcare Conference, the most important venue of the sector, three M&A deals were announced, raising expectations for a return of industry consolidation and much-needed support for biotech companies. 16 March 2023
Biotechnology
Provention Bio’s shares skyrocketed 262% to $24.27 in pre-market trading today, on the news that French pharma major Sanofi had made a takeover bid for the US biotech. 13 March 2023
Biotechnology
An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's newly-announced $43 billion takeover of Seagen. 13 March 2023
Biotechnology
Given that early merger talks between Pfizer and Seagen had already been reported, the confirmation of the deal was not a surprise, but the price was a great deal more than the around $30 billion previously rumored. 13 March 2023
Biotechnology
The strategic venture capital unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has put its weight behind a $100 million boost for a new precision medicine company. 8 March 2023
Biotechnology
Shares of UK cell therapy specialist Adaptimmune Therapeutics and Cambridge, USA-based TCR² Therapeutics moved in opposite directions this morning, as they announced plans to merge. 6 March 2023
Biotechnology
A merger between Flamingo Therapeutics and Dynacure will create a new oncology company, retaining the Flamingo name, advancing lead candidates danvatirsen and FTX-001. 3 March 2023
Biotechnology
The Dutch business of Rhythm Pharmaceuticals has acquired Xinvento, a Netherlands-based biotech focused on therapies for congenital hyperinsulinism (CHI). 27 February 2023
Biotechnology
Last week’s important regulatory news included the US Food and Drug Administration (FDA) approving Travere Therapeutics’ Filspari for the reduction of proteinuria in adults with primary IgAN. Among research news, Actinium Pharmaceuticals released positive Phase III data on its myeloid leukemia candidate Iomab-12. On the M&A front, troubled US drug developer Jounce Therapeutics found a ‘white knight’, entering a reverse merger with the UK’s Redx Pharma. Deal-making saw AstraZeneca sign a licensing agreement with China-based KYM Biosciences for CMG901, a potential gastric cancer treatment to expand its own portfolio. Also, having already forked out around $1 billion in upfront and milestone payments, Swiss pharma giant Roche terminated its agreement with US biotech Blueprint Medicines on the cancer drug Gavreto. 26 February 2023
Biotechnology
Struggling to finance further development of its immunotherapy candidates alone, Jounce Therapeutics has announced plans to merge with British firm Redx Pharma. 23 February 2023
Biotechnology
French biotech firms Erytech Pharma and Pherecydes Pharma today announced they intend to merge their operations and relocate all teams to Erytech’s premises in Lyon, France, where they would benefit from presence in a major European hub for infectious diseases. 16 February 2023
Biotechnology
Israel-based clinical-stage company Purple Biotech saw its shares gains 9.5% to 61.00 shekels today, as announced that it has entered into an agreement to acquire Netherlands-headquartered, venture capital backed Immunorizon. 2 February 2023
Biotechnology
An analysis of the recent progress in RNA therapeutics and future opportunities. 31 January 2023
Biotechnology
M&A news featured in the past week, with the announcement that Leap Therapeutics is to merge with Flame Biosciences, with the aim of advancing its anti-claudin 18.2 asset. Also, Elicio Therapeutics entered into a reverse merger deal with Angion, which will see the former list on the Nasdaq. Additionally, India’s Sun Pharmaceutical Industries is shelling out $576 million to acquire Concert Pharmaceuticals and its alopecia candidate deuruxolitinib. Meanwhile, US mRNA vaccine specialist Moderna released positive new data on its respiratory syncytial virus (RSV) vaccine. On the regulatory front, the US Food and Drug Administration (FDA) declined to grant accelerated approval for Eli Lilly’s Alzheimer’s candidate donanemab, issuing a complete response letter CRL. 22 January 2023
Biotechnology
After a difficult year for investment, look for the biotech industry to engage in creative dealmaking in the market, leading to faster innovation in the lab, Protagonist Therapeutics CEO Dinesh Patel writes in Bio.News. 20 January 2023
Biotechnology
Neurodegenerative diseases specialist APRINOIA Therapeutics has announced a merger with Ross Acquisition Corp II, a special purpose acquisition company (SPAC) founded by former US Secretary of Commerce Wilbur Ross. 18 January 2023
Biotechnology
Privately-held US cancer drug biotech Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. 18 January 2023
Biotechnology
Cambridge, Massachusetts-based oncology specialist Leap Therapeutics has bought the privately-owned company Flame Biosciences. 17 January 2023
Biotechnology
The past week kicked off with several M&A deals being announced. The largest of these was by UK pharma major AstraZeneca revealing that is acquiring CinCor Pharma for up to $1.8 billion, with the aim of expanding it cardiorenal portfolio and pipeline as well as blood pressure drug baxdrostat. Also, French drugmaker Ipsen announced a takeover bid for USA-based Albireo in a deal worth almost $1 billion, bringing with it rights to liver disease drug Bylvay. Arecor Therapeutics reached a key milestone in the development of the ready-to-use injectable AT307 in its partnership with Hikma Pharmaceuticals but the latter also returned rights to another candidate, AT282. Privately-held US mRNA specialist Anima Biotech entered into a collaboration with US pharma major AbbVie to develop cancer and immune disorder therapies. 15 January 2023
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze